CMD Bioscience and Research Foundation of SUNY on Behalf of Stony Brook University Sign Exclusive Licensing Agreement
News Apr 28, 2008
The deal gives CMD Bioscience exclusive control of a computational method for predicting protein-protein and protein-peptide binding affinities. The algorithm has enormous implications for computer-aided drug design.
“We are very excited about obtaining an exclusive license for this software from the Research Foundation of SUNY on behalf of Stony Brook University,” said Dr. Joseph Audie, the CEO and founder of CMD Bioscience. “This program gives us a competitive advantage and enhances our ability to rationally design proteins and peptides for our biotech and pharmaceutical partners.”
CMD Bioscience is a Connecticut-based company that uses proprietary computational methods to solve problems of biological and therapeutic interests. Formed in 2006, the company was founded by Dr. Joseph Audie of Meriden, CT., Ph.D.
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.